Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

ConclusionA significant proportion of patients with severe colitis failing IV steroids responded to induction therapy with CT-P13. Colectomy-free survival rates were similar to previous randomized trials using originator infliximab as induction therapy in severe steroid-refractory colitis.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research